Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Ann Trop Med Parasitol ; 96(7): 707-15, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12537632

RESUMEN

The encephalopathy that sometimes develops after ivermectin treatment in patients with high Loa microfilaraemias is probably related to a massive effect of the drug on the Loa microfilariae. A trial was therefore conducted to evaluate whether a course of albendazole would bring about a slower decrease in the Loa microfilaraemia, and thus could be used as a mass 'clearing' treatment, before the distribution of ivermectin in areas where onchocerciasis and loiasis are co-endemic. The Loa microfilarial loads were followed monthly for 9 months in two groups of subjects, one treated with albendazole (400 mg twice a day for 3 days), and the other with vitamin (B(1), B(6) and B(12)) tablets. There were no significant between-group differences in the microfilarial loads at any of the examination rounds. During the follow-up period, there was also no significant change in the overall loads among those treated with albendazole, although the counts in those with high initial microfilaraemias (>8000 microfilariae/ml) tended to decrease progressively during the first 3 months. Further trials should now be performed, to evaluate the effects on Loa loa of two courses of albendazole given 2-3 months apart.


Asunto(s)
Albendazol/administración & dosificación , Filaricidas/administración & dosificación , Loiasis/tratamiento farmacológico , Parasitemia/tratamiento farmacológico , Adolescente , Adulto , Anciano , Animales , Camerún , Niño , Esquema de Medicación , Femenino , Humanos , Ivermectina/efectos adversos , Loa/efectos de los fármacos , Masculino , Microfilarias/efectos de los fármacos , Persona de Mediana Edad , Estadísticas no Paramétricas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...